Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma

Clinical Advances in Hematology and Oncology

Volumn 10, Issue 4, 2012, Pages 240-246

  Hainsworth, John D ^a   Shih, Kent C ^a   Shepard, Gregg C ^a   Tillinghast, Guy W ^b   Brinker, Brett T ^c   Spigel, David R ^a  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b Peninsula Cancer Institute   (United States)

^c GRAND RAPIDS CLINICAL ONCOLOGY PROGRAM   (United States)

Author keywords

Bevacizumab; Brain tumor; Everolimus; Glioblastoma

Indexed keywords

BEVACIZUMAB; EVEROLIMUS; TEMOZOLOMIDE;

ADULT; AGED; ANEMIA; ARTERY THROMBOSIS; ARTICLE; BLEEDING; DEATH; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; EMBOLISM; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; GLIOBLASTOMA; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIA; LUNG EMBOLISM; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; NAUSEA; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIMARY MEDICAL CARE; PROTEINURIA; RASH; STOMATITIS; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT RESPONSE; VEIN THROMBOSIS; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DACARBAZINE; DISEASE-FREE SURVIVAL; FEMALE; GLIOBLASTOMA; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; SIROLIMUS; YOUNG ADULT;

EID: 84859628071     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996.
2. Vredenburgh JJ, Desjardins A, Herndon JE, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007;25:4722-4729.
3. Bokstein F, Shpigel S, Blumenthal DT. Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors. Cancer. 2008;112:2267-2273.
4. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27:740-745.
5. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27:4733-4740.
6. Cloughesy T, Vrendenburgh JJ, Day B, et al. Updated safety and survival of patients with relapsed glioblastoma treated with bevacizumab in the BRAIN study. J Clin Oncol (ASCO Annual Meeting Abstracts). 2010;28: Abstract 2008.
7. Gruber ML, Raza S, Gruber D, Narayana A. Bevacizumab in combination with radiotherapy plus concomitant and adjuvant temozolomide for newly diagnosed glioblastoma: update progression-free survival, overall survival, and toxicity. J Clin Oncol (ASCO Annual Meeting Abstracts). 2009;27: Abstract 2017.
8. Chakravarti A, Zhai G, Suzuki Y, et al. The prognostic significance of phosphatidyl inositol 3-kinase pathway activation in human gliomas. J Clin Oncol. 2004;22:1926-1933.
9. Liu W, James CD, Frederick L, et al. PTEN/MMAC1 mutations and EGFR amplification in glioblastomas. Cancer Res. 1997;57:5254-5261.
10. Zafar Y, Bendell J, Lager J, et al. Preliminary results of a phase I study of bevacizumab in combination with everolimus in patients with advanced solid tumors. J Clin Oncol (ASCO Annual Meeting Abstracts). 2006;24: Abstract 3097.
11. Hainsworth JD, Spigel DR, Burris HA, et al. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J Clin Oncol. 2010;28:2131-2136.
12. Hainsworth JD, Infante JR, Spigel DR, et al. Bevacizumab and everolimus in the treatment of patients with metastatic melanoma: a phase II trial of the Sarah Cannon Oncology Research Consortium. Cancer. 2010;116:4122-4129.
13. MacDonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277-1280.
14. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
15. Reardon DA, Fink KL, Mikkelsen T, et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol. 2008;26:5610-5617.
16. Reardon DA, Egorin MJ, Desjardins A, et al. Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma. Cancer. 2009;115:2188-2198.
17. Lai A, Tran A, Nghiemphu PL, et al. Phase II trial of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol. 2010;29:142-148.
18. Vredenburgh JJ, Desjardins A, Reardon DA, et al. Bevacizumab (BEV) in combination with temozolomide (TMZ) and radiation therapy (XRT) followed by BEV, TMZ, and irinotecan for newly diagnosed glioblastoma multiforme. J Clin Oncol (ASCO Annual Meeting Abstracts). 2010;28: Abstract 2013.
19. Omuro Am, Beal K, Karimi S, et al. Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma (GBM). J Clin Oncol (ASCO Annual Meeting Abstracts). 2010;28: Abstract 2036.